Inve US ▾
ICICUI

ICU Medical (ICUI) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Health Care· May 7, 2026

Source: earnings call transcript

Executive summary

ICU Medical Q1 FY26 — Strong Infusion Systems Growth and Gross Margin Expansion

ICU Medical delivered solid Q1 FY26 results, marked by strong organic growth in its core IV Systems business and sequential gross margin expansion. While facing headwinds from the IV Solutions deconsolidation and increased logistics costs, the company reaffirmed its full-year guidance, anticipating offsets from lower tariffs and accelerated operational efficiencies. Management is focused on deleveraging and exploring strategic options for the Vital Care portfolio.

Highlights

5

  • Total company organic revenue grew 1% in Q1 FY26.

  • Gross margins increased sequentially to over 41%.

  • IV Systems business grew 6% organically, marking a record quarter in pumps.

  • Adjusted EPS increased 15% to $1.97.

  • Free cash flow was strong at $28 million.

Concerns

4

  • Total company reported revenue decreased 12% due to the deconsolidation of IV Solutions.

  • Vital Care organic revenue decreased 14% due to SKU discontinuations.

  • FDA clearances for new Medfusion and CADD hardware platforms are delayed due to increased testing requirements.

  • An estimated $10 million in additional logistics expense is projected for 2026 due to higher oil/diesel prices.

Guidance & targets

CategoryTargetConfidence
Full-year guidance
Reaffirmed
high materiality
High
IV Systems growth cadence
More balanced throughout the year
medium materiality
High
Cash consumed in integration and remediation activities
Materially decrease later in the year, down sequentially in Q2
medium materiality
High
Gross margin target
2 percentage points of opportunity remaining
high materiality
High
Net leverage target
2x or less
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Consumables
Q1 revenues were in line with expectations, down sequentially like prior years. Expect growth rates to return to historical levels in Q2.
—5% reported, 2% organicdown sequentially—
IV Systems
Expect organic growth to continue at this rate or above, absorbing OEM wind down. Growth will be more balanced throughout the year, not back-half weighted.
Record quarter in pumps
—8% reported, 6% organic——
Vital Care
Reported decrease due to deconsolidation of IV Solutions. Organic decrease due to discontinuing certain SKUs to improve profitability, with largest impact in Q1. Expect sequential stability to improvement organically, near-term revenue flat to slightly down.
—decreased 14% organic, decreased 59% reported——

ICUI operating KPIs by quarter

ICUI operating KPIs stated on its earnings calls, by fiscal quarter
KPIThis call Mar 2026 Q1 FY26 Jun 2026 Q2 FY26Change vs prior quarter
Capital expenditures General maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the US
$11M During the quarter, we invested $9 million of cash spend for quality system and product-related remediation activities, $17 million on restructuring and integration and $11 million on CapEx for general maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the US Source: earnings call transcript
$19M During the quarter, we invested $11 million of cash spend for quality system and product-related remediation activities, $11 million on restructuring and integration and $19 million on CapEx for general maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the US Source: earnings call transcript
+72.7%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

ProductTypeDetails
Oncology line product (Clave connectors + IV bags)launch
Revised disinfection cap (SwabCap portfolio)launch
LifeShield safety software (latest version)update

Deals & partnerships

Otsuka Creation of Otsuka ICU Medical joint venture and resulting deconsolidation of IV Solutions from income statement.

Joint venture created in mid-2025, modernizing the IV Solutions business.

Risks & headwinds

Increased logistics costs due to higher oil/diesel prices 2026

Estimated $10 million additional logistics expense in 2026

Mitigation:Partially offset by lower tariffs in Q2/Q3 and accelerated operational efficiencies.

FDA delays for new infusion pump hardware clearances Near-term

Additional testing data required (larger sample size, more set configurations)

Mitigation:Prioritizing Medfusion testing, then CADD. Company has expertise with 6 prior 510(k) clearances.

Uncertainty around future tariff framework Beyond Q3 FY26

Current Section 122 tariffs are temporary; not known what new framework may replace them.

Mitigation:Not assuming benefit from lower Section 122 tariffs will continue beyond expiration.

What to watch in Q2 FY26

IV Systems organic growth rate

Q2 FY26
Current 6%
Target Continue at this rate or above

Why it matters

Indicates sustained momentum in a core business and successful rebalancing of installation cadence.

For Q2 and the near term, we would expect organic growth to continue at this rate or above while absorbing the previously mentioned OEM wind down.

Find out whether ICUI delivers this. Inve re-checks your case every morning.

Q&A highlights

What was the LVP growth in Q1 for Infusion Systems?

Vivek Jain stated that LVP was the strongest growth driver in the Infusion Systems segment, but the company prefers to reflect on specific business line growth at year-end.

“the strongest growth driver was LVP by far and away in the segment.”

asked by Jayson Bedford · answered by Vivek Jain

2 min read 5 chapters

Detailed narrative

Q1 Performance Overview

ICU Medical reported Q1 FY26 revenue of $526 million, reflecting 1% organic growth but a 12% reported decrease due to the mid-2025 deconsolidation of the Otsuka ICU Medical joint venture. Gross margins improved sequentially to over 41%, driven by a favorable product mix towards higher-margin consumables and infusion businesses. Adjusted EBITDA was $99 million, flat year-over-year, while adjusted EPS increased 15% to $1.97.

Product Development & Regulatory Updates

The company received two new 510(k) clearances for consumables: an oncology line product bonding Clave connectors to IV bags and a revised disinfection cap for the SwabCap portfolio. On Infusion Systems, FDA approval was received for the latest LifeShield safety software version. However, new Medfusion and CADD hardware submissions face delays due to increased FDA testing requirements for larger sample sizes, with Medfusion prioritized.

Macroeconomic Headwinds & Offsets

Management highlighted an estimated $10 million in additional logistics expense for 2026 due to higher oil and diesel prices. This is expected to be largely offset by slightly lower tariff expenses in Q2 and Q3 (due to Section 122 rates being less than IEEPA rates) and accelerated operational efficiencies. The company is not factoring in potential IEEPA refunds into its guidance.

Strategic Priorities & Capital Allocation

ICU Medical aims to build a comprehensive infusion therapy company by focusing on innovation in consumables and systems, optimizing its manufacturing network, and improving earnings power. The company is actively pursuing operational and strategic choices for the Vital Care portfolio, including exiting certain non-core SKUs like Japanese surgical commodities. A key financial goal is to achieve 2x or less net leverage, which they are within half a turn of, through organic cash flow or strategic moves.

IV Systems Growth Rebalancing

The company initially expected IV Systems growth to be back-half weighted but now anticipates a more balanced growth trajectory throughout the year. This shift is attributed to improved synchronization of installation resources and customer scheduling for new product rollouts, helping manage near-term volatility.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.